June 5th, 2026 | 07:00 CEST
Global Food Security Meets Agritech Innovation: New Developments from Bayer, Nutrien, and MustGrow Biologics
Created and published on behalf of MustGrow Biologics Corp.
Global hunger has been rising dramatically for years and already affects over 750 million people worldwide. Geopolitical conflicts such as the war in Ukraine, the pandemic's aftermath, and intensifying droughts driven by the climate crisis are exposing the extreme vulnerability of our global food supply. To permanently reverse this dangerous trend, development organizations like Bread for the World are calling for a profound, ecological transformation away from pure agribusiness toward sustainable, resilient systems. In this context, agribusiness conglomerates and innovative pioneer companies are under significant pressure to deliver effective solutions quickly. But how are established industry leaders responding to these historic challenges, and what role do innovative organic approaches play in this future market worth hundreds of billions? A look at current market trends reveals where the momentum for a new era in agriculture is building.
time to read: 4 minutes
|
Author:
Matthias Schomber
ISIN:
MUSTGROW BIOLOGICS CORP. | CA62822A1030 | TSXV: MGRO , OTCQB: MGROF , BAYER AG NA O.N. | DE000BAY0017 , NUTRIEN LTD | CA67077M1086
Table of contents:
Author
Matthias Schomber
Raised in Giessen, Hesse, Matthias Schomber discovered his passion for the financial markets as early as the 1990s—at a time when stock trading was still largely the domain of true, die-hard traders. After completing his banking apprenticeship, he worked for a private bank there and witnessed the rise and fall of the Neuer Markt firsthand on the trading floor of the Frankfurt Stock Exchange, drawing lessons from the experience that continue to shape his thinking as a trader, author, and trading system developer to this day.
Tag cloud
Shares cloud
Current Figures and Developments at Bayer and Nutrien
The Leverkusen-based chemical and pharmaceutical company Bayer is pushing ahead full steam with the transformation of its Crop Science agricultural business. In its recently released figures for the first quarter of 2026, the company reported a solid start to the year. Group revenue rose by just over 4% on a currency- and portfolio-adjusted basis to EUR 13.4 billion, while EBITDA before special items increased by 9% to EUR 4.4 billion. Despite this positive operational start, challenges in traditional chemical crop protection were evident, as the herbicide business—and glyphosate-based products in particular—suffered significant declines in prices and sales, as expected. CEO Bill Anderson is therefore consistently refocusing the division on higher-margin and more innovative products to make the company more resilient in the long term. At the same time, Bayer announced in early June 2026 that, despite ongoing pressure from approximately 100,000 pending US lawsuits involving the weed killer Roundup, there are currently no plans to spin off the Monsanto subsidiary. Instead, the focus is entirely on resolving the legacy legal issues and strengthening the core business areas operationally.
Our attention shifts from Bayer to Canada. There, Canadian fertilizer giant Nutrien Ltd. also posted robust first-quarter 2026 operating performance. Thanks to continued strong global demand and stable prices, Nutrien achieved adjusted EBITDA of USD 1.10 billion. A key driver here was a historic record volume in global potash sales. At the same time, management is advancing a comprehensive review of its strategic options. These include potential sales or partnerships for the phosphate business, the Trinidad nitrogen plant, and retail operations in Brazil, with the aim of structurally improving earnings quality and free cash flow. To optimize its capital structure, Nutrien also successfully placed new senior notes totalling USD 1 billion at the end of May 2026 to flexibly service upcoming maturities and secure working capital for the coming season.
Biological Innovation
While established industry giants such as Bayer and Nutrien manage massive global supply chains while simultaneously making far-reaching portfolio adjustments, the structural problems of purely chemical-synthetic agriculture highlight the need for new solutions and approaches. The call for soil health, humus buildup, and the preservation of biodiversity is growing louder to feed the planet and its ever-growing population in the long term. It is precisely at this intersection that smaller but innovative and specialized companies bridge the gap between industrial yield requirements and ecological sustainability. They provide the biological technologies that large corporations increasingly need to license or acquire in order to meet their own climate goals and legal requirements.
MustGrow Biologics: Commercial Milestones and Technical Opportunities
The Canadian company MustGrow Biologics Corp. plays a key role in this group of innovative companies. By harnessing the natural, organic defence mechanisms found in mustard seeds, MustGrow develops biological pesticides and soil treatment products that leave no chemical residues.
At the end of May 2026, the company reported its first-quarter financial results, marking its transition into the commercial phase of its development. The first commercial revenue was generated with the organic biofertility product TerraSante™, coupled with a solid gross margin of 23.6%. While the company still reported a net loss, this was reduced by USD 0.3 million compared with the prior-year period, indicating improving operational efficiency.
The commercial rollout is also gaining regulatory momentum. In line with this, MustGrow received official approvals to commence commercial sales for TerraSante™ in the US states of Texas, Utah, and Montana on May 25, 2026. The large market of Texas, in particular, represents a significant opportunity in the high-value fruit and vegetable cultivation sector.
To transition production from batch-based manufacturing to continuous large-scale production lines and to meet growing demand in the US, MustGrow is looking to secure additional capital. On May 25, 2026, the company announced a strategic LIFE private placement that is expected to generate approximately CAD 2 million in gross proceeds. Confidence in the technology is not new. Industry leaders such as Bayer have already been testing and licensing MustGrow's mustard-derived biological solutions through exclusive global partnerships covering selected regions.
Technical Analysis
From a technical analysis perspective, MustGrow shares look extremely promising at the current level. With the issue price of the latest financing round at CAD 0.50, the stock has established a very robust horizontal support level. If the share now manages a dynamic breakout above the CAD 0.60 mark, the path is clear from a technical perspective for a rapid rally toward the chart-recognized previous highs of CAD 0.75-0.80. As soon as the psychologically important hurdles at CAD 0.95 and CAD 1.00 are sustainably overcome, the stock could generate another buy signal, opening up medium-term price targets in the range of CAD 1.20 to 1.30.
Conclusion: Three Approaches to a Common Goal
The transformation of global agriculture in the fight against global hunger requires both the enormous scalability of large corporations and the innovative strength of smaller players. Bayer is performing well operationally, with a fairly solid start to the year, but remains under structural pressure due to US litigation related to Monsanto. Nutrien is leveraging persistently high fertilizer demand to achieve record volumes while optimizing its global portfolio through strategic divestitures. MustGrow Biologics, on the other hand, serves as a speculative play that, with initial commercial revenue, new US state approvals, and a solid chart base at CAD 0.50, represents a highly attractive option for forward-looking investors.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
